Natural Capsules Limited · NSE:NATCAPSUQ

Natural Capsules — Q1 FY27 Earnings Presentation

29 slides from Natural Capsules's earnings presentation, Aug 13, 2026

  1. Slide 1: Cover letter to stock exchanges

    S\)\OSE <" NHTUHHL 150 150 e Fle N- c fl P S U Le S 9001 :2015 }14001 :2015] " + i Qqualky environmental ey % o Management// Management // Hiah &55fe F L %, & e g gy (c] LIMITGD VG - Caps CORP & REGD OFFICE : “ TRIDENT TOWERS” No. 23. 4th Floor, 100 2nd Block, Bangalore-560011 Phone : 080-26561562 /

  2. Slide 2: Investor Presentation

    ( '\ "NHTURHL naturalcapsules.com CAPSULES S LIMITED Investor . Presentation BSE: 524654 AUGUST, 2026 NSE: NATCAPSUQ

  3. Slide 3: Safe Harbor

    Safe Harbor INVESTOR PRESENTATION Certain statements and opinions with respect to the anticipated future performance of Natural Capsules Limited (NCL) in the presentation (“forward - looking statements”), which reflect various assumptions concerning the strategies, objectives and anticipated results

  4. Slide 4: Inside this document

    Inside this document INVESTOR PRESENTATION QUARTERLY COMPANY BUSINESS HIGHLIGHTS OVERVIEW CANVAS o w FINANCIAL INVESTMENT s PERFORMANCE MERITS = =} “n I o > n o < U o < ™~ > = < z 3

  5. Slide 5: Quarterly Highlights

    aaaaaaaaaaaaaaaaaaa Quarterly Highlights

  6. Slide 6: Quarterly Updates — Q1FY27 (Consolidated)

    Quarterly Updates — Q1FY27 (Consolidated) INVESTOR PRESENTATION REVENUES X48.71 Cr EBITDA 1.12Cr ® (17%) Q-0-Q ® (16%) Q-0-Q ® 8% Y-0-Y ® 251% Y-o-Y EBITDA MARGINS 2.30% PAT (X5.74 Cr) ® 2BPS Q-0-Q ® 15%Q-0-Q ® 159 BPS Y-0-Y ® 3% Y-0-Y o s « EPS (X 5.55) B) @ a < o ® 15% Q-0-Q < o > pus ® 3%Y-0-Y <

  7. Slide 7: Management Commentary

    Management Commentary INVESTOR PRESENTATION "QIFY27 was a strong operational quarter for the capsules business. As communicated previously, the reported numbers are notdirectly comparable to the preceding quarter, which had benefited from the dispatch of deferred inventory following the Puducherry p

  8. Slide 8: Profit & Loss Statement Summary (consolidated)

    Profit & Loss Statement Summary (consolidated) :< . = s PARTICULARS ( IN CRORES) Q1FY26 QA4FY26 Q1FY27 Q-0-Q Y-o-Y E Revenue From Operations 45.20 58.45 48.71 -17% 8% = s Other Income 036 076 235 208% 556% = Total Income 45.56 59.22 51.06 -14% 12% Total Operating Expenses 44.88 57.12 47.59 -17% 6% E

  9. Slide 9: Company Overview

    aaaaaaaaaaaaaaaaaaa Company Overview

  10. Slide 10: Introducing Natural Capsules Limited (NCL)

    Introducing Natural Capsules Limited (NCL) © P < = Natural Capsules Limited (NCL) is a hard capsule shell manufacturer, who pioneered manufacturing of « vegetarian capsules in India and is the second largest Indian manufacturer for gelatin capsules. The o o 311 company was incorporated as a Public L

  11. Slide 11: Our Journey

    Our Journey STODR PRESEN 1993- 2014: EARLY SUCCESSES AND A PERIOD OF EXPANSION XD DD* NCL was * Soon after, in D EIND CIXD * 2003 was an * The coming * In 2005-2007, NCL 50D O * In 2009-2012, *In 2012-14, NCL incorporated in 2001, NCL important decade witnessed acquired 5 lines NCL acquired upgraded

  12. Slide 12: Our Journey: 2015-2018 hurdles and going forward

    2015 - 2018: THE HURDLES WE GOING FORWARD FACED ON THE WAY Installed capacity as at FY26 stands at 20.25 BCPA Fall in oil and commaodity prices led to economic 2019 onward NCL witnessed an increase in slowdown in African countries and caused a demand in both domestic and export markets, One new HPMC

  13. Slide 13: Product Offerings

    Product Offerings INVESTOR PRESENTATION Natural Capsules Limited manufactures a vast array capsules, including vegetarian capsules which they have pioneered in India. The company is now foraying into APl manufacturing with complex CAPSULES APIs high-end patented technology developed in-house, under

  14. Slide 14: Global Presence

    Global Presence Natural Capsules exports to 28 countries across 5 continents, bringing in sizable revenue from its export. % OF EXPORT SALES AFRICA Cis * Ghana « Georgia * Kenya « Uzbekistan 0% H * Nigeria * Turkey as - . * South Africa * Russian Federation - * Tunisia « Uganda MIDDLE EAST ) 0% < Zi

  15. Slide 15: Serving Leading Brands

    Serving Leading Brands INVESTOR PRESENTATION With over 3 decades of CUSTOMERS FOR REPEAT BUSINESS MORE THAN 10 YEARS DURING FY26 experience in the pharma 30% of total customers 80% of total turnover sector, NCL has garnered excellent relationship with customers across 28 countries. CUSTOMERS FOR MOR

  16. Slide 16: Board of Directors

    Board of Directors Mr. Laxminarayan Mundra Mr. Satyanarayana Mundra Mr. Sushil Kumar Mundra Mr. Sunil Mundra WHOLE TIME DIRECTOR WHOLE TIME DIRECTOR DIRECTOR MANAGING DIRECTOR >4 Mr. Pramod Kasat Mr. TY Prabhu \ ey Mr. S G Belapure Mrs. Jyothi Mundra INDEPENDENT DIRECTOR CHAIRMAN & INDEPENDENT INDEP

  17. Slide 17: Business Canvas

    aaaaaaaaaaaaaaaaaaa Business Canvas

  18. Slide 18: Capsules Segment

    Capsules Segment o o < = ©n With almost three decades of experience in the industry, Natural Capsules o Limited is a leading manufacturer of hard capsules in India, its products o are exported to regulated and unregulated markets across the globe, an largest o« o s following stringent applicable rul

  19. Slide 19: API Segment

    API Segment o = < = Natural Capsules Limited is now foraying into the API business segment 2 through its subsidiary - Natural Biogenex Private Limited (NBPL) Greenfield Capex at < incorporated in 2020. The APIs that will be manufactured 'gumkur, spread across e X . acres are,Hydrocortisone, Predniso

  20. Slide 20: PLI Scheme incentive for APIs

    The scheme intends to boost domestic manufacturing of identified KSMs, Drug Intermediates and APIs by 6 attracting large investments in the sector and thereby reduce India’s import dependence in critical APlIs. With a view to attain self-reliance and reduce import A committee on drug security consti

  21. Slide 21: Focus on R&D

    Focus on R&D = < = NCL strongly believes in investing in R&D, to stay ahead of its peers and to E consistently innovate. The Company’s recent entry into the API business is 2 DSIR S a testament to its firm belief in R&D. Recognised state of the g art R&D facilities i E R&D SPENDS & KEY AREAS OF RESE

  22. Slide 22: naturalcapsules.com

    naturalcapsules.com

  23. Slide 23: Profit & Loss Statement Summary (Consolidated)

    Profit & Loss Statement Summary (Consolidated) INVESTOR PRESENTATION PARTICULARS ( IN CRORES) FY22 FY23 FY24 FY25 FY26 Revenue from Operations 135.07 172.37 155.42 169.21 187.20 Other Income 1.01 0.57 1.94 0.70 173 Total Income 136.08 172.94 157.36 169.91 188.94 Total Operating Expenses 109.69 137.3

  24. Slide 24: Balance Sheet Summary (Consolidated)

    Balance Sheet Summary (Consolidated) INVESTOR PRESENTATION PARTICULARS (X IN CRORES) FY22 FY23 FY24 FY25 FY26 Total Equity (Networth) 82.98 148.25 228.80 257.16 234.72 Non-Current Liabilities 34.85 73.57 71.23 62.20 56.71 Current Liabilities 46.45 66.89 76.49 99.99 13273 Total Equity and Liability 1

  25. Slide 25: Cash Flow Statement Summary (Consolidated)

    Cash Flow Statement Summary (Consolidated) © P < = « o PARTICULARS (X IN CRORES) FY22 FY23 FY24 FY25 FY26 o o o ° «n > Cash Flow from Operating Activities 1.16 17.22 (8.35) 26.75 10.92 Cash Flow from Investing Activities (45.88) (104.63) (72.59) (44 .48) (10.77) Cash Flow from Financing Activities 4

  26. Slide 26: Investment Merits

    aaaaaaaaaaaaaaaaaaa Investment Merits

  27. Slide 27: Growth Drivers

    Growth Drivers y &5 =) fi Capacity enhancement with Being the only backward Exploring opportunities The Company will benefit state-of-the-art machinery integrated manufacturer to set up capsules from strong industry tailwinds in capsules division, enabling of steroidal APIs in India, manufacturing fa

  28. Slide 28: Strategic Priorities

    . . ey Strategic Priorities 5 z E NCL is geared to bring about @}3 E monumental changes in its e e the oroains CAREX. the approach towards its business. 1 STRATEGIC PRIORITY - ACTIONS TAKEN ° > Company is enabling itself to o . . . . = b th ket leader i * Positioning the business to reduce margin *

  29. Slide 29: Thank You

    NATURAL naturalcapsules.com CAPSULES LIMITED Thank You CONTACT US FOR FURTHER INFORMATION, PLEASE CONTACT Natural Capsules Limited Mr. Raj Kishore Prasad Mr. Abhishek Mehra TRIDENT TOWERS, CHIEF FINANCIAL OFFICER INVESTOR RELATIONS ADVISOR Fourth Floor, No. 23, +91 95588 14500 100 Feet Road, Jaynaga

Natural Capsules — Q1 FY27 Earnings Presentation on 6ix